Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 195 of 195 results for sepsis

  1. Service provision for neutropenic sepsis in patients with cancer:- A prospective national cohort study should be carried out to assess the incidence of suspected and proven neutropenic sepsis in patients having anticancer treatment.

    Recommendation ID CG151/1 Question Service provision for neutropenic sepsis in patients with cancer:- A prospective national cohort...

    Research recommendation
    Published
    9 June 2015

  2. Signs and symptoms that predict neutropenic sepsis in the community:- A prospective study should be carried out to determine which signs and symptoms experienced by patients in the community predict neutropenic sepsis and the outcomes of these episodes.

    CG151/3 Question Signs and symptoms that predict neutropenic sepsis in the community:- A prospective study should be carried out to...

    Research recommendation
    Published
    9 June 2015

  3. Reducing the risk of complications of anticancer treatment in children and young people, and in adults diagnosed with lymphoma:- Randomised studies should investigate primary prophylaxis of neutropenic sepsis in 2 populations: children and young people (aged under 18) having treatment for solid tumours or haematological malignancies, or stem cell transplantation; and adults (aged 18 and older) diagnosed with lymphoma. The studies should compare the effectiveness of fluoroquinolone antibiotics given alone, fluoroquinolone antibiotics given together with G-CSF preparations, and G-CSF preparations given alone. Outcome measures should include overall mortality, infectious episodes and adverse events. In addition, quality of life should be determined using quantitative and qualitative methods. The resulting data should be used to develop a cost-effectiveness analysis comparing these 3 forms of prophylaxis in children and young people having anticancer treatment, and in adults diagnosed with lymphoma.

    Randomised studies should investigate primary prophylaxis of neutropenic sepsis in 2 populations: children and young people (aged under...

    Research recommendation
    Published
    9 June 2015

  4. Switching from inpatient intravenous to outpatient oral antibiotic therapy in patients with neutropenic sepsis:- A randomised controlled trial should be undertaken to evaluate the clinical and cost effectiveness of stopping intravenous antibiotic therapy and switching to oral therapy within the first 24 hours of treatment in patients with neutropenic sepsis who are having treatment with intravenous antibiotics. The outcomes to be measured are overtreatment, death, need for critical care, length of hospital stay, duration of fever and quality of life.

    intravenous to outpatient oral antibiotic therapy in patients with neutropenic sepsis:- A randomised controlled trial should be...

    Research recommendation
    Published
    9 June 2015

  5. Patient support and information:- A descriptive study involving patients who have had neutropenic sepsis and their carers should be undertaken to find out what types of support and information patients and carers were given, which of these they found helpful or unhelpful, and whether they think additional or different types of support or information are needed.

    information:- A descriptive study involving patients who have had neutropenic sepsis and their carers should be undertaken to find out...

    Research recommendation
    Published
    9 June 2015

  6. Xpert GBS test for the intrapartum detection of group B streptococcus (MIB28)

    NICE has developed a medtech innovation briefing (MIB) on Xpert GBS test for the intrapartum detection of group B streptococcus

    Medtech innovation briefing
    Published
    21 April 2015

  7. Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)

    Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection

    Evidence summary
    Published
    17 March 2015

  8. Shiley Endotracheal Tube with TaperGuard Cuff for intensive care patients at risk of ventilator‑associated pneumonia (MIB22)

    NICE has developed a medtech innovation briefing (MIB) on the Shiley Endotracheal Tube with TaperGuard Cuff .

    Medtech innovation briefing
    Published
    2 March 2015

  9. Safe midwifery staffing for maternity settings (NG4)

    This guideline covers safe midwifery staffing in all maternity settings, including at home, in the community, in day assessment units, in obstetric units, and in units led by midwives (both alongside hospitals and free-standing). It aims to improve maternity care by giving advice on monitoring staffing levels and actions to take if there are not enough midwives to meet the needs of women and babies in the service.

    NICE guideline
    Published
    27 February 2015
    View recommendations

    Sections for NG4

  10. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

    Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.

    Technology appraisal guidance
    Published
    25 February 2015
    View recommendations

    Sections for TA329

  11. The SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of the biliary system (MIB21)

    NICE has developed a Medtech Innovation Briefing (MIB) on the SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of

    Medtech innovation briefing
    Published
    12 February 2015

  12. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

    Evidence summary
    Published
    10 February 2015

  13. Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)

    Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the

    Diagnostics guidance
    Published
    10 December 2014
    View recommendations

    Sections for DG16

  14. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (DG13)

    Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems)

    Diagnostics guidance
    Published
    20 August 2014
    View recommendations

    Sections for DG13

  15. The hTEE system for transoesophageal echocardiographic monitoring of haemodynamic instability (MIB7)

    NICE has developed a Medtech Innovation Briefing (MIB) on the hTEE system for transoesophageal echocardiographic monitoring of haemodynamic instability

    Medtech innovation briefing
    Published
    11 August 2014

  16. Pressure ulcers: prevention and management (CG179)

    This guideline covers risk assessment, prevention and treatment in children, young people and adults at risk of, or who have, a pressure ulcer (also known as a bedsore or pressure sore). It aims to reduce the number of pressure ulcers in people admitted to secondary or tertiary care or receiving NHS care in other settings, such as primary and community care and emergency departments.

    Clinical guideline
    Published
    23 April 2014
    View recommendations

    Sections for CG179

  17. Extracorporeal membrane oxygenation (ECMO) for acute heart failure in adults (IPG482)

    Evidence-based recommendations on extracorporeal membrane oxygenation (ECMO) for acute heart failure in adults. This involves using an artificial lung to oxygenate the blood outside the body.

    Interventional procedures guidance
    Published
    27 March 2014
    View recommendations

    Sections for IPG482

  18. Faecal microbiota transplant for recurrent Clostridium difficile infection (IPG485)

    Evidence-based recommendations on faecal microbiota transplant for recurrent Clostridium difficile infection. This involves introducing enteric bacteria from the faeces of healthy donors to restore a healthy balance of bacteria in the gut.

    Interventional procedures guidance
    Published
    27 March 2014
    View recommendations

    Sections for IPG485

  19. The NGAL Test for early diagnosis of acute kidney injury (MIB3)

    NICE has developed a medtech innovation briefing (MIB) on the NGAL Test for early diagnosis of acute kidney injury .

    Medtech innovation briefing
    Published
    4 February 2014

  20. The RhinoChill intranasal cooling system for reducing temperature after cardiac arrest (MIB4)

    NICE has developed a Medtech Innovation Briefing (MIB) on the RhinoChill intranasal cooling system

    Medtech innovation briefing
    Published
    1 February 2014

  21. Negative pressure wound therapy for the open abdomen (IPG467)

    Evidence-based recommendations on negative pressure wound therapy for the open abdomen. This involves using a small pump to remove infected material, stop fluid escaping and help the wound heal.

    Interventional procedures guidance
    Published
    27 November 2013
    View recommendations

    Sections for IPG467

  22. Acute upper gastrointestinal bleeding in adults (QS38)

    This quality standard covers the management of acute upper gastrointestinal bleeding in adults and young people (aged 16 and over). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    30 July 2013
    View quality statements

    Sections for QS38

  23. Irreversible electroporation for treating primary lung cancer and metastases in the lung (IPG441)

    Evidence-based recommendations on irreversible electroporation for treating primary lung cancer and metastases in the lung. This involves using electrical pulses to kill cancer cells.

    Interventional procedures guidance
    Published
    23 February 2013
    View recommendations

    Sections for IPG441

  24. Irreversible electroporation for treating renal cancer (IPG443)

    Evidence-based recommendations on irreversible electroporation (IRE) for treating renal cancer. This involves using electrical pulses to kill cancer cells, applied directly to the tumour through special needles.

    Interventional procedures guidance
    Published
    23 February 2013
    View recommendations

    Sections for IPG443

  25. Irreversible electroporation for treating liver metastases (IPG445)

    Evidence-based recommendations on irreversible electroporation for the treatment of liver metastases. This involves using very short electrical field pulses delivered over several minutes to destroy the tumour and a small surrounding tissue margin.

    Interventional procedures guidance
    Published
    23 February 2013
    View recommendations

    Sections for IPG445

  26. Neutropenic sepsis: prevention and management in people with cancer (CG151)

    This guideline covers preventing, identifying and managing neutropenic sepsis in children, young people and adults receiving treatment for cancer in the community and in secondary and tertiary care. It aims to reduce the risk of infection in people with neutropenia (low number of white blood cells) who are receiving anticancer treatment and improve management of neutropenic sepsis.

    Clinical guideline
    Published
    19 September 2012
    View recommendations

    Sections for CG151

  27. Extracorporeal membrane oxygenation for severe acute respiratory failure in adults (IPG391)

    Evidence-based recommendations on extracorporeal membrane oxygenation for severe acute respiratory failure in adults. This involves using a tube to carry blood from the right side of the heart and then pump it through an artificial lung where it picks up oxygen.

    Interventional procedures guidance
    Published
    27 April 2011
    View recommendations

    Sections for IPG391

  28. Percutaneous retroperitoneal endoscopic necrosectomy (IPG384)

    Evidence-based recommendations on percutaneous retroperitoneal endoscopic necrosectomy. This involves inserting a thin telescope through a small cut in the side above the hip and using it to wash out and remove the dead tissue.

    Interventional procedures guidance
    Published
    23 March 2011
    View recommendations

    Sections for IPG384

  29. Thoracoscopic repair of congenital diaphragmatic hernia in neonates (IPG379)

    Evidence-based recommendations on thoracoscopic repair of congenital diaphragmatic hernia in neonates. This involves inserting surgical instruments through small cuts in the chest, and then moving the abdominal organs out of the chest and repairing the diaphragm.

    Interventional procedures guidance
    Published
    25 January 2011
    View recommendations

    Sections for IPG379

  30. Cryotherapy for the treatment of liver metastases (IPG369)

    Evidence-based recommendations on cryotherapy for the treatment of liver metastases. This involves using cold temperatures applied through a special needle to destroy the cancer cells.

    Interventional procedures guidance
    Published
    15 December 2010
    View recommendations

    Sections for IPG369

  31. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

    Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    25 August 2010
    View recommendations

    Sections for TA199

  32. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they haven’t worked well enough.

    Technology appraisal guidance
    Published
    25 August 2010
    View recommendations

    Sections for TA195

  33. Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy (IPG274)

    Evidence-based recommendations on autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy. This involves removing parts of the pancreas (islet cells) after the pancreas has been removed and inserting them into the liver to restart insulin production.

    Interventional procedures guidance
    Published
    24 September 2008
    View recommendations

    Sections for IPG274

  34. Total wrist replacement (IPG271)

    Evidence-based recommendations on total wrist replacement. This involves creating an artificial wrist joint consisting of metal implants attached to the end of the arm and to the hand, separated by a spacer to allow movement.

    Interventional procedures guidance
    Published
    27 August 2008
    View recommendations

    Sections for IPG271

  35. Adalimumab for the treatment of adults with psoriasis (TA146)

    Evidence-based recommendations on adalimumab (Humira) for treating psoriasis in adults.

    Technology appraisal guidance
    Published
    25 June 2008
    View recommendations

    Sections for TA146

  36. Laparoscopic mobilisation of the greater omentum for breast reconstruction (IPG253)

    Evidence-based recommendations on laparoscopic mobilisation of the greater omentum for breast reconstruction. This involves removing the fatty tissue using special instruments through small cuts in the abdomen.

    Interventional procedures guidance
    Published
    27 February 2008
    View recommendations

    Sections for IPG253

  37. Serial transverse enteroplasty procedure (STEP) for bowel lengthening in parenteral nutrition-dependent children (IPG232)

    Evidence-based recommendations on the serial transverse enteroplasty procedure (STEP) for bowel lengthening in parenteral nutrition-dependent children. This involves cutting and stapling the bowel in a zig-zag pattern to narrow and lengthen it.

    Interventional procedures guidance
    Published
    26 September 2007
    View recommendations

    Sections for IPG232

  38. Percutaneous laser therapy for fetal tumours (IPG180)

    Evidence-based recommendations on percutaneous laser therapy for fetal tumours. This involves inserting a needle through the mother's abdomen to the tumour and using laser energy to shrink it.

    Interventional procedures guidance
    Published
    28 June 2006
    View recommendations

    Sections for IPG180

  39. Living-donor lung transplantation for end-stage lung disease (IPG170)

    Evidence-based recommendations on living-donor lung transplantation for end-stage lung disease. This involves removing a lung from each of the two donors and replacing the recipient's lungs with the donor lungs.

    Interventional procedures guidance
    Published
    24 May 2006
    View recommendations

    Sections for IPG170

  40. Drotrecogin alfa (activated) for severe sepsis (TA84)

    November 2011 On 25 October 2011, Eli Lilly and Company announced the withdrawal of its Xigris (drotrecogin alfa [activated]) product in all markets following results of the PROWESS–SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock. The company is working with regulatory agencies on this withdrawal, and is in the process of notifying healthcare professionals and clinical trial investigators. As a result of this, NICE has withdrawn its guidance on the use of drotrecogin alfa (activated) for severe sepsis.

    Technology appraisal guidance
    Published
    22 September 2004

  41. Fallopian tube recanalisation by guidewire (IPG71)

    Evidence-based recommendations on fallopian tube recanalisation by guidewire. This involves injecting dye through a narrow tube inserted into the fallopian tube and if this doesn't unblock it, using a guidewire.

    Interventional procedures guidance
    Published
    28 July 2004
    View recommendations

    Sections for IPG71

  42. Balloon angioplasty of pulmonary vein stenosis in infants (IPG75)

    Evidence-based recommendations on balloon angioplasty of pulmonary vein stenosis in infants. This involves involves inflating a balloon in the narrow section of the pulmonary vein to widen the area so blood can flow through more easily.

    Interventional procedures guidance
    Published
    28 July 2004
    View recommendations

    Sections for IPG75

  43. Suspected sepsis: recognition, diagnosis and early management

    NICE is updating its guideline on suspected sepsis: recognition, diagnosis and early management (NG51) . Updates in progress For people...

    NICE guideline
    In development

  44. Sepsis

    All NICE products on sepsis. Includes any guidance and advice.

    Topic page

  45. Suspected sepsis: recognition, diagnosis and early management

    In development [GID-NG10412] Expected publication date: 13 August 2025

    NICE guideline
    In development